Search
Abagovomab
go.drugbank.com/drugs/DB16077InvestigationalAbagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
AZD8630
go.drugbank.com/drugs/DB19397InvestigationalAZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics
Melitracen
go.drugbank.com/drugs/DB13384InvestigationalCategories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOmzotirome
go.drugbank.com/drugs/DB16046InvestigationalTRC150094 is under investigation in clinical trial NCT03254446 (Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension).
Ziltivekimab
go.drugbank.com/drugs/DB18836InvestigationalZiltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).
BTA9881
go.drugbank.com/drugs/DB05226InvestigationalBTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Fluoromisonidazole F-18
go.drugbank.com/drugs/DB14830InvestigationalFluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small
PF-06882961
go.drugbank.com/drugs/DB16043InvestigationalPF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
AIM-102
go.drugbank.com/drugs/DB16176InvestigationalAIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic